K131351

# 510(k) SUMMARY

<table><tr><td colspan="2">510(k) Owner: 4 Henderson Drive</td><td colspan="2">Alfa Wassermann Diagnostic Technologies, LLC</td></tr><tr><td>Date Summary Prepared:</td><td rowspan="3">Contact:</td><td colspan="2">West Caldwell, NJ 07006 Hkatz@AlfaWassermannUS.com</td></tr><tr><td colspan="3">Hyman Katz, Ph.D. Phone: 973-852-0158 Fax: 973-852-0237</td></tr><tr><td colspan="3">July 3, 2013 Trade Name:</td></tr><tr><td>Device:</td><td colspan="2">Classification: Common/Classification Name:</td><td>ACE Alkaline Phosphatase Reagent</td></tr><tr><td rowspan="10"></td><td colspan="2"></td><td>Nitrophenylphosphate, Alkaline Phosphatase Or Isoenzymes</td></tr><tr><td colspan="2"></td><td>(21 C. F.R. § 862.1050) Product Code CJE</td></tr><tr><td colspan="2">Trade Name:</td><td></td></tr><tr><td colspan="2">Classification:</td><td>ACE Amylase Reagent Class 2</td></tr><tr><td colspan="2">Common/Classification Name:</td><td>Saccharogenic, Amylase (21 C. F.R. § 862.1070)</td></tr><tr><td colspan="2">Trade Name:</td><td>Product Code CIJ</td></tr><tr><td colspan="2">Classification:</td><td>ACE ALT Reagent Class 1</td></tr><tr><td colspan="2">Common/Classification Name:</td><td>NADH Oxidation/NAD Reduction, ALT/SGPT</td></tr><tr><td colspan="2"></td><td>(21 C.F.R. § 862.1030) Product Code CKA</td></tr><tr><td colspan="2">Trade Name:</td><td>ACE AST Reagent</td></tr><tr><td rowspan="3"></td><td>Classification:</td><td>Class 2</td></tr><tr><td>Common/Classification Name:</td><td>NADH Oxidation/NAD Reduction, AST/SGOT</td></tr><tr><td>(21 C.F.R. § 862.1 100) Product Code CIT</td><td></td></tr><tr><td colspan="2">Predicate Devices: Reagents (K113253, K931786, K930104, K113436, K1 13382)</td><td colspan="2">Manufacturer for reagent system predicates: Alfa Wassermann ACE and ACE Axcel Clinical Chemistry Systems and ACE</td></tr><tr><td>Device</td><td>In the ACE Alkaline Phosphatase Reagent assay, alkaline phosphatase catalyzes the hydrolysis of colorless p-nitrophenyl phosphate to p-nitrophenol and inorganic</td></tr><tr><td rowspan="5">Descriptions:</td><td>phosphate. In an alkaline solution (pH 10.5), p-nitrophenol is in the phenoxide form and has a strong absorbance at 408 nm. The rate of increase in absorbance, monitored bichromatically at 408 nm/486 nm, is directly proportional to the alkaline phosphatase activity in the sample.</td></tr><tr><td>In the ACE Amylase Reagent assay, α-amylase hydrolyzes the 2-chloro-p-nitrophenyl- α-D-maltotrioside substrate to release 2-chloro-p-nitrophenol and form 2-chloro-p- nitrophenyl-α-D-maltoside, maltotriose and glucose. The rate of increase in absorbance, monitored bichromatically at 408 nm/ 647 nm, is directly proportional to the α-amylase activity in the sample.</td></tr><tr><td>In the ACE ALT Reagent assay, alanine aminotransferase converts the L-alanine and α- ketoglutarate substrates in the reagent to L-glutamate and pyruvate, respectively. Lactate dehydrogenase (LDH) catalyzes the oxidation of the reduced cofactor to the cofactor. The rate of conversion of the reduced cofactor to the cofactor can be determined by monitoring the decrease in absorbance bichromatically at 340 nm/647 nm. This rate of conversion from the reduced cofactor to the cofactor is a function of</td></tr><tr><td>the activity of ALT in the sample. In the ACE AST Reagent assay, aspartate aminotransferase converts the L-aspartate and α-ketoglutarate in the reagent to oxaloacetate and L-glutamate, respectively. The oxaloacetate undergoes reduction, with concurrent oxidation of NADH to NAD+ in the malate dehydrogenase-catalyzed indicator reaction. NADH absorbs strongly at 340 nm, whereas NAD* does not. Therefore, the rate of conversion of NADH to NAD+ can be</td></tr><tr><td>determined by monitoring the decrease in absorbance bichromatically at 340 nm/647 nm. This rate of conversion from NADH to NAD* is a function of the activity of AST in the sample. Lactate dehydrogenase is added to prevent interference from endogenous</td></tr><tr><td rowspan="2">Intended Use: diagnosis and treatment of pancreatitis (inflammation of the pancreas). This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.</td><td>pyruvate, which is normally present in blood. Indications for Use: The ACE Alkaline Phosphatase Reagent is intended for the quantitative determination of alkaline phosphatase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Measurements of alkaline phosphatase are used in the diagnosis and treatment of liver, bone, parathyroid, and</td></tr><tr><td>intestinal diseases. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only. The ACE Amylase Reagent is intended for the quantitative determination of α-amylase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Amylase measurements are used primarily for the</td></tr><tr><td>Intended Use:</td><td>The ACE ALT Reagent is intended for the quantitative determination of alanine aminotransferase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Alanine aminotransferase measurements are used in the diagnosis and treatment of certain liver diseases (e.g., viral hepatitis and cirrhosis) and heart diseases. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only. The ACE AST Reagent is intended for the quantitative determination of aspartate aminotransferase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Measurements of aspartate aminotransferase are used in the diagnosis and treatment of certain types of liver and</td></tr><tr><td>Technological Characteristics:</td><td>The ACE Alkaline Phosphatase Reagent is composed of two reagent bottles (Buffer and Substrate Reagent). The reagents contain AMP Buffer (pH 10.45), magnesium acetate, and p-nitrophenyl phosphate. The ACE Amylase Reagent is composed of a single reagent bottle. The reagents contain 2-chloro-p-nitrophenyl-α-D-maltotrioside, sodium chloride, calcium acetate, potassium thiocyanate, and MES buffer (pH 6.0). The ACE ALT Reagent consists of two reagent bottles (Substrate and Coenzyme). The reagents contain L-alanine, α-ketoglutarate, nicotinamide adenine dinucleotide-reduced (NADH), lactate dehydrogenase, and Tris buffer. The ACE AST Reagent consists of two reagent bottles (Substrate and Coenzyme). The reagents contain L-aspartate, α-ketoglutarate, nicotinamide adenine dinucleotide-</td></tr></table>

# Comparison of similarities and differences with predicate device

Device Comparison with Predicate   
ACE Alkaline Phosphatase Reagent   

<table><tr><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK931786(ACE ALP)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE Alkaline Phosphatase Reagent is intendedfor the quantitative determination of alkalinephosphatase activity.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel Clinical ChemistrySystems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>Not a calibrated test</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>SA2002: 20 DaysRX2002: 7 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>4μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>169 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>44 - 147 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>9 - 1400 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Serum ALP is stable for 7 days at 4-8°C and for 2months at -20°C</td><td rowspan=1 colspan=1>Same</td></tr></table>

# ACE Amylase Reagent

<table><tr><td rowspan=1 colspan=1>AMYLASE</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK931786(ACE Amylase)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE Amylase Reagent is intended for thequantitative determination of α-amylase activity.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>Not a calibrated test</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>3μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>168 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>20 - 104 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>9 - 1900 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Serum amylase is stable for 7 days at roomtemperature (18-26°C) and at 4°C for one month.Recommended storage is at 4°C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

Device Comparison with Predicate   

<table><tr><td rowspan=1 colspan=3>ACE ALT Reagent</td></tr><tr><td rowspan=1 colspan=1>ALT</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Device2 K930104(ACE ALT)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE ALT Reagent is intended for thequantitative determination of alanineaminotransferase activity concentration.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>Not a calibrated test</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>13 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>185 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>5 - 30 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>4 - 480 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Specimen is stable for 7 days at 4-8°C and -20°C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# ACE AST Reagent

<table><tr><td rowspan=1 colspan=1>AST</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK930104(ACE AST)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE AST Reagent is intended for thequantitative determination of aspartateaminotransferase activity.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>Not a calibrated test</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>13 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>185 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>7-31 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>4-450 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Specimen activity is stable for 28 days at 4°C andat least one year at -20°</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td>Performance Data: In-House Precision- Serum vs. Plasma</td></tr></table>

In-House Precision: Serum vs. Plasma - ACE Alkaline Phosphatase Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)</td></tr><tr><td rowspan=2 colspan=1>ALP(n=20)</td><td rowspan=1 colspan=3>ACE</td><td rowspan=1 colspan=3>Alera</td><td rowspan=1 colspan=3>Axcel</td></tr><tr><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>1.2,1.3%</td><td rowspan=1 colspan=1>1.9,2.0%</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>0.8,0.9%</td><td rowspan=1 colspan=1>2.0,2.2%</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>1.2,1.3%</td><td rowspan=1 colspan=1>2.1,2.3%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>649</td><td rowspan=1 colspan=1>6.3,1.0%</td><td rowspan=1 colspan=1>8.6,1.3%</td><td rowspan=1 colspan=1>642</td><td rowspan=1 colspan=1>6.4,.1.0%</td><td rowspan=1 colspan=1>6.41.0%</td><td rowspan=1 colspan=1>645</td><td rowspan=1 colspan=1>6.8,1.0%</td><td rowspan=1 colspan=1>6.9,1.1%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>1198</td><td rowspan=1 colspan=1>20.2,1.7%</td><td rowspan=1 colspan=1>20.8,1.7%</td><td rowspan=1 colspan=1>1190</td><td rowspan=1 colspan=1>5.6,0.5%</td><td rowspan=1 colspan=1>8.7,0.7%</td><td rowspan=1 colspan=1>1194</td><td rowspan=1 colspan=1>6.1,0.5%</td><td rowspan=1 colspan=1>7.9,0.7%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>1.9,2.5%</td><td rowspan=1 colspan=1>2.8,3.7%</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>0.8,1.1%</td><td rowspan=1 colspan=1>3.4,4.6%</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>1.1,1.5%</td><td rowspan=1 colspan=1>3.7,5.1%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>614</td><td rowspan=1 colspan=1>5.8,0.9%</td><td rowspan=1 colspan=1>24.4,4.0%</td><td rowspan=1 colspan=1>609</td><td rowspan=1 colspan=1>5.1,0.8%</td><td rowspan=1 colspan=1>20.2,3.3%</td><td rowspan=1 colspan=1>613</td><td rowspan=1 colspan=1>3.4,0.6%</td><td rowspan=1 colspan=1>20.5,3.3%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>1163</td><td rowspan=1 colspan=1>6.8,0.6%</td><td rowspan=1 colspan=1>33.5,2.9%</td><td rowspan=1 colspan=1>1149</td><td rowspan=1 colspan=1>5.9,0.5%</td><td rowspan=1 colspan=1>32.9,2.9%</td><td rowspan=1 colspan=1>1155</td><td rowspan=1 colspan=1>7.6,0.7%</td><td rowspan=1 colspan=1>35.7,3.1%</td></tr></table>

In-House Precision: Serum vs. Plasma = ACE Amylase Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)</td></tr><tr><td rowspan=2 colspan=1>AMY(n=20)</td><td rowspan=1 colspan=3>•          ACE</td><td rowspan=1 colspan=3>Alera</td><td rowspan=1 colspan=3>Axcel</td></tr><tr><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0.7,1.5%</td><td rowspan=1 colspan=1>0.9,2.1%</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>1.0,2.1%</td><td rowspan=1 colspan=1>1.5,3.3%</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>1.2,2.6%</td><td rowspan=1 colspan=1>1.6,3.4%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>830</td><td rowspan=1 colspan=1>9.2,1.1%</td><td rowspan=1 colspan=1>11.5,1.4%</td><td rowspan=1 colspan=1>825</td><td rowspan=1 colspan=1>5.1,0.6%</td><td rowspan=1 colspan=1>11.9,1.4%</td><td rowspan=1 colspan=1>826</td><td rowspan=1 colspan=1>9.2,1.1%</td><td rowspan=1 colspan=1>11.9,1.4%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>1597</td><td rowspan=1 colspan=1>15.0,0.9%</td><td rowspan=1 colspan=1>19.8,1.2%</td><td rowspan=1 colspan=1>1577</td><td rowspan=1 colspan=1>9.9,0.6%</td><td rowspan=1 colspan=1>29.4,1.9%</td><td rowspan=1 colspan=1>1586</td><td rowspan=1 colspan=1>8.5,0.5%</td><td rowspan=1 colspan=1>18.6,1.2%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>0.7,1.8%</td><td rowspan=1 colspan=1>1.3,3.2%</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0.5,1.3%</td><td rowspan=1 colspan=1>1.5,3.5%</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>1.0,2.5%</td><td rowspan=1 colspan=1>2.5,6.0%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>806</td><td rowspan=1 colspan=1>8.1,1.0%</td><td rowspan=1 colspan=1>12.5,1.5%</td><td rowspan=1 colspan=1>801</td><td rowspan=1 colspan=1>4.4,0.5%</td><td rowspan=1 colspan=1>13.1,1.6%</td><td rowspan=1 colspan=1>.805</td><td rowspan=1 colspan=1>5.3,0.7%</td><td rowspan=1 colspan=1>12.2,1.5%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>1604</td><td rowspan=1 colspan=1>15.4,1.0%</td><td rowspan=1 colspan=1>29.3,1.8%</td><td rowspan=1 colspan=1>1596</td><td rowspan=1 colspan=1>18.8,1.2%</td><td rowspan=1 colspan=1>33.8,2.1%</td><td rowspan=1 colspan=1>.1604</td><td rowspan=1 colspan=1>21.6,1.3%</td><td rowspan=1 colspan=1>25.0,1.6%</td></tr></table>

In-House Precision: Serum vs. Plasma - ACE ALT Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)</td></tr><tr><td rowspan=2 colspan=1>ALT(n=24)</td><td rowspan=1 colspan=3>ACE</td><td rowspan=1 colspan=3>Alera</td><td rowspan=1 colspan=3>Axcel</td></tr><tr><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>0.9,2.6%</td><td rowspan=1 colspan=1>1.4,4.0%</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>0.6,1.7%</td><td rowspan=1 colspan=1>1.2,3.3%</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>1.1,3.1%</td><td rowspan=1 colspan=1>1.4,3.7%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>1.3,1.2%</td><td rowspan=1 colspan=1>1.8,1.6%</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>1.3,1.1%</td><td rowspan=1 colspan=1>2.2,2.0%</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>1.4,1.2%</td><td rowspan=1 colspan=1>2.3,2.0%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>2.9,1.4%</td><td rowspan=1 colspan=1>4.0,1.9%</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>1.8,0.8%</td><td rowspan=1 colspan=1>3.5,1.6%</td><td rowspan=1 colspan=1>218</td><td rowspan=1 colspan=1>1.4,0.6%</td><td rowspan=1 colspan=1>3.2,1.5%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0.9,2.7%</td><td rowspan=1 colspan=1>1.3,4.0%</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0.8,2.6%</td><td rowspan=1 colspan=1>1.5,4.7%</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>1.0,2.9%</td><td rowspan=1 colspan=1>1.4,4.1%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>·112</td><td rowspan=1 colspan=1>1.1,1.0%</td><td rowspan=1 colspan=1>1.5,1.4%</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>0.9,0.8%</td><td rowspan=1 colspan=1>1.1,1.0%</td><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>1.0,0.9%</td><td rowspan=1 colspan=1>1.5,1.4%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>1.1,0.5%</td><td rowspan=1 colspan=1>1.6,0.7%</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>2.1,0.9%</td><td rowspan=1 colspan=1>3.0,1.4%</td><td rowspan=1 colspan=1>222</td><td rowspan=1 colspan=1>1.7,0.7%</td><td rowspan=1 colspan=1>2.7,1.2%</td></tr></table>

In-House Precision: Serum vs. Plasma - ACE AST Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)</td></tr><tr><td rowspan=2 colspan=1>AST(n=24)</td><td rowspan=1 colspan=3>ACE</td><td rowspan=1 colspan=3>Alera</td><td rowspan=1 colspan=3>Axcel</td></tr><tr><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0.7,2.6%</td><td rowspan=1 colspan=1>1.2,4.5%</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0.7,2.7%</td><td rowspan=1 colspan=1>0.8,3.3%</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1.1,4.3%</td><td rowspan=1 colspan=1>1.4,5.7%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>1.3,0.8%</td><td rowspan=1 colspan=1>2.7,1.8%</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>1.0,0.7%</td><td rowspan=1 colspan=1>2.8,1.8%</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>0.7,0.5%</td><td rowspan=1 colspan=1>2.3.1.5%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>301</td><td rowspan=1 colspan=1>3.5,1.2%</td><td rowspan=1 colspan=1>4.8,1.6%</td><td rowspan=1 colspan=1>302</td><td rowspan=1 colspan=1>2.2,0.7%</td><td rowspan=1 colspan=1>4.0,1.3%</td><td rowspan=1 colspan=1>304</td><td rowspan=1 colspan=1>2.7,0.9%</td><td rowspan=1 colspan=1>4.1,1.4%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0.8,3.2%</td><td rowspan=1 colspan=1>1.4.5.4%</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0.6,2.5%</td><td rowspan=1 colspan=1>1.0,3.7%</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0.9,3.5%</td><td rowspan=1 colspan=1>1.0,4.0%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>1.6,1.0%</td><td rowspan=1 colspan=1>2.3 ,1.4%</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>1.5,0.9%</td><td rowspan=1 colspan=1>1.7,1.1%</td><td rowspan=1 colspan=1>158</td><td rowspan=1 colspan=1>1.4,0.9%</td><td rowspan=1 colspan=1>2.0,1.3%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>304</td><td rowspan=1 colspan=1>3.5,1.2%</td><td rowspan=1 colspan=1>4.5,1.5%</td><td rowspan=1 colspan=1>303</td><td rowspan=1 colspan=1>2.6 ,0.9%</td><td rowspan=1 colspan=1>3.9,1.3%</td><td rowspan=1 colspan=1>305</td><td rowspan=1 colspan=1>3.2,1.1%</td><td rowspan=1 colspan=1>4.3,1.4%</td></tr></table>

<table><tr><td>Performance Data: In-House Matrix Comparison Serum vs. Plasma</td></tr></table>

Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE, ACE Alera and ACE Axcel Clinical Chemistry Systems

In-House Matrix Comparison: Serum vs. Plasma - ACE ALP Reagent   

<table><tr><td>System</td><td>Range</td><td colspan="2">Results - Serum vs. Plasma</td></tr><tr><td>ACE</td><td></td><td>Slope:</td><td>0.998</td></tr><tr><td rowspan="5">108 pairs</td><td rowspan="5">9 - 1274 U/L</td><td>Intercept:</td><td>-8.3</td></tr><tr><td>Correlation:</td><td>0.9980</td></tr><tr><td>Std. Error Est:</td><td>13.5</td></tr><tr><td>Confidence Interval Slope:</td><td>0.986 to 1.010</td></tr><tr><td>Confidence Interval Intercept:</td><td>-11.5 to -5.1</td></tr><tr><td rowspan="5">ACE Alera 108 pairs</td><td rowspan="5">9 - 1202 U/L</td><td>Slope:</td><td>0.983</td></tr><tr><td>Intercept:</td><td>-6.4</td></tr><tr><td>Correlation:</td><td>0.9952</td></tr><tr><td>Std. Error Est:</td><td>20.2</td></tr><tr><td>Confidence Interval Slope:</td><td>0.965 to 1.002</td></tr><tr><td>ACE Axcel</td><td></td><td>Confidence Interval Intercept:</td><td>-11.2 to -1.6</td></tr><tr><td rowspan="5">62 pairs</td><td rowspan="5">11 - 1222 U/L</td><td>Slope:</td><td>1.017</td></tr><tr><td>Intercept:</td><td>-6.5</td></tr><tr><td>Correlation:</td><td>0.9982</td></tr><tr><td>Std. Error Est:</td><td>14.5</td></tr><tr><td>Confidence Interval Slope: Confidence Interval Intercept:</td><td>1.001 to 1.033</td></tr></table>

In-House Matrix Comparison: Serum vs. Plasma - ACE Amylase Reagent   

<table><tr><td>System</td><td>Range</td><td>Results - Serum vs. Plasma</td><td></td></tr><tr><td>ACE</td><td rowspan="6">11 - 1766 U/L</td><td>Slope:</td><td>0.977</td></tr><tr><td rowspan="5">104 pairs</td><td>Intercept:</td><td>1.7</td></tr><tr><td>Correlation:</td><td>0.9995</td></tr><tr><td>Std. Error Est:</td><td>8.8</td></tr><tr><td>Confidence Interval Slope:</td><td>0.970 to 0.983</td></tr><tr><td>Confidence Interval Intercept:</td><td>-0.2 to 3.6</td></tr><tr><td>ACE Alera</td><td rowspan="6">11 - 1703 U/L</td><td>Slope:</td><td>0.979</td></tr><tr><td rowspan="5">101 pairs</td><td>Intercept:</td><td>0.9</td></tr><tr><td>Correlation:</td><td>0.9994</td></tr><tr><td>Std. Error Est:</td><td>9.0</td></tr><tr><td>Confidence Interval Slope:</td><td>0.972 to 0.986</td></tr><tr><td>Confidence Interval Intercept:</td><td>-1.0 to 2.9</td></tr><tr><td>ACE Axcel</td><td></td><td>Slope:</td><td>0.994</td></tr><tr><td rowspan="5">52 pairs</td><td></td><td>Intercept:</td><td>-1.76</td></tr><tr><td>10 - 1890 U/L</td><td>Correlation:</td><td>0.9996</td></tr><tr><td></td><td>Std. Error Est:</td><td>11.54</td></tr><tr><td></td><td>Confidence Interval Slope:</td><td>0.986 to 1.002</td></tr><tr><td></td><td>Confidence Interval Intercept:</td><td>-5.33 to 1.80</td></tr></table>

<table><tr><td>Performance Data: In-House Matrix Comparison- Serum vs. Plasma</td><td></td></tr></table>

In-House Matrix Comparison: Serum vs. Plasma - ACE ALT Reagent   

<table><tr><td>System</td><td>Range</td><td colspan="2">Results - Serum vs. Plasma</td></tr><tr><td>ACE</td><td rowspan="6">4 - 460 U/L</td><td>Slope:</td><td>1.003</td></tr><tr><td rowspan="5">54 pairs</td><td>Intercept:</td><td>-3.6</td></tr><tr><td>Correlation:</td><td>0.9994</td></tr><tr><td>Std. Error Est:</td><td>2.8</td></tr><tr><td>Confidence Interval Slope:</td><td>0.994 to 1.013</td></tr><tr><td>Confidence Interval Intercept:</td><td>-4.5 to -2.8</td></tr><tr><td>ACE Alera</td><td rowspan="6">5 - 463 U/L</td><td>Slope:</td><td>1.000</td></tr><tr><td rowspan="5">52 pairs</td><td>Intercept:</td><td>-3.6</td></tr><tr><td>Correlation:</td><td>0.9986</td></tr><tr><td>Std. Error Est:</td><td>4.3</td></tr><tr><td>Confidence Interval Slope:</td><td>0.985 to 1.015</td></tr><tr><td>Confidence Interval Intercept:</td><td>-4.9 to -2.2</td></tr><tr><td>ACE Axcel</td><td></td><td>Slope:</td><td>0.985</td></tr><tr><td rowspan="5">56 pairs</td><td rowspan="5">6 - 469 U/L</td><td>Intercept:</td><td>-3.35</td></tr><tr><td>Correlation:</td><td>0.9993</td></tr><tr><td>Std. Error Est:</td><td></td></tr><tr><td></td><td>2.94</td></tr><tr><td>Confidence Interval Slope: Confidence Interval Intercept:</td><td>0.976 to 0.995 -4.24 to -2.47</td></tr></table>

In-House Matrix Comparison: Serum vs. Plasma  ACE AST Reagent   

<table><tr><td>System</td><td>Range</td><td colspan="2">Results - Serum vs. Plasma</td></tr><tr><td>ACE</td><td rowspan="6">4 - 404 U/L</td><td>Slope:</td><td>0.981</td></tr><tr><td rowspan="5">53 pairs</td><td>Intercept:</td><td>0.7</td></tr><tr><td>Correlation:</td><td>0.9992</td></tr><tr><td>Std. Error Est:</td><td>3.2</td></tr><tr><td>Confidence Interval Slope:</td><td>0.971 to 0.992</td></tr><tr><td>Confidence Interval Intercept:</td><td>-0.3 to 1.7</td></tr><tr><td>ACE Alera</td><td rowspan="6">4 - 396 U/L</td><td>Slope:</td><td>0.999</td></tr><tr><td rowspan="5">52 pairs</td><td>Intercept:</td><td>-0.6</td></tr><tr><td>Correlation:</td><td>0.9989</td></tr><tr><td>Std. Error Est:</td><td>3.9</td></tr><tr><td>Confidence Interval Slope:</td><td>0.985 to 1.012</td></tr><tr><td>Confidence Interval Intercept:</td><td>-1.9 to 0.6</td></tr><tr><td>ACE Axcel</td><td rowspan="6">4 - 408 U/L</td><td>Slope:</td><td>1.001</td></tr><tr><td rowspan="5">52 pairs</td><td>Intercept:</td><td>0.22</td></tr><tr><td>Correlation:</td><td>0.9989</td></tr><tr><td>Std. Error Est:</td><td>3.97</td></tr><tr><td>Confidence Interval Slope:</td><td></td></tr><tr><td>Confidence Interval Intercept:</td><td>0.987 to 1.014 -1.04 to 1.49</td></tr></table>

<table><tr><td>Performance Data: Precision - POL</td></tr></table>

# POL - Precision for ACE and ACE Alera Clinical Chemistry Systems

(Note: Please refer to previously cleared submissions k113436 (ALP and Amylase) and k1 13382 (ALT and AST) for ACE Axcel POL data)

<table><tr><td rowspan=2 colspan=3>ALP</td><td rowspan=1 colspan=2>ACE Results</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>ACE Alera Results</td></tr><tr><td rowspan=1 colspan=2>U/L SD, %CV</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>U/L SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>59.</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.4</td><td rowspan=2 colspan=1>60</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>55</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.3</td><td rowspan=2 colspan=1>56</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>54</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.6</td><td rowspan=2 colspan=1>59</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>57</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.5</td><td rowspan=2 colspan=1>56</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>5.4%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>648</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>6.7</td><td rowspan=2 colspan=1>653</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>1.1%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>632</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>13.4</td><td rowspan=2 colspan=1>626</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>16.7</td></tr><tr><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>631</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>11.9</td><td rowspan=2 colspan=1>659</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>18.0</td></tr><tr><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>642</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>8.6</td><td rowspan=2 colspan=1>640</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>21.9</td></tr><tr><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>1191</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>10.7</td><td rowspan=2 colspan=1>1192</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>13.4</td></tr><tr><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.1%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>1145</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>23.0</td><td rowspan=2 colspan=1>1135</td><td rowspan=1 colspan=1>19.0</td><td rowspan=1 colspan=1>25.0</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>1159</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>17.2</td><td rowspan=2 colspan=1>1209</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>29.3</td></tr><tr><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>1185</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>7.3</td><td rowspan=2 colspan=1>1165</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>37.2</td></tr><tr><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>3.2%</td></tr></table>

Performance

Data at POL:

Precision - POL

# POL - Precision for ACE and ACE Alera Clinical Chemistry Systems

<table><tr><td rowspan=2 colspan=3>AMY</td><td rowspan=1 colspan=3>ACE Results</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>ACE Alera Results</td></tr><tr><td rowspan=1 colspan=3>U/L SD, %CV</td><td rowspan=1 colspan=2>U/L SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>39</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=2>1.3</td><td rowspan=2 colspan=1>39</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=2>3.2%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>37</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=2>1.2</td><td rowspan=2 colspan=1>38</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=2>3.2%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>4.4%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>39</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=2>0.9</td><td rowspan=2 colspan=1>40</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=2>2.4%</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>39</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=2>1.1</td><td rowspan=2 colspan=1>39</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=2>2.7%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>2.8%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>741</td><td rowspan=1 colspan=2>7.1</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>747</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>7.3</td></tr><tr><td rowspan=1 colspan=2>1.0%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>725</td><td rowspan=1 colspan=2>4.6</td><td rowspan=1 colspan=1>11.5</td><td rowspan=2 colspan=1>723</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=2>0.6%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>727</td><td rowspan=1 colspan=2>7.4</td><td rowspan=1 colspan=1>8.2</td><td rowspan=2 colspan=1>770</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>6.1</td></tr><tr><td rowspan=1 colspan=2>1.0%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>737</td><td rowspan=1 colspan=2>9.6</td><td rowspan=1 colspan=1>11.3</td><td rowspan=2 colspan=1>747</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>7.4</td></tr><tr><td rowspan=1 colspan=2>1.3%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=8>.</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>1429</td><td rowspan=1 colspan=2>7.5</td><td rowspan=1 colspan=1>13.1</td><td rowspan=2 colspan=1>1437</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>12.8</td></tr><tr><td rowspan=1 colspan=2>0.5%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>1389</td><td rowspan=1 colspan=2>18.1</td><td rowspan=1 colspan=1>27.8</td><td rowspan=1 colspan=1>1388</td><td rowspan=1 colspan=1>19.5</td><td rowspan=1 colspan=1>21.6</td></tr><tr><td rowspan=1 colspan=2>1.3%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1388</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>1401</td><td rowspan=1 colspan=2>22.4</td><td rowspan=1 colspan=1>23.8</td><td rowspan=2 colspan=1>1500</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>11.7</td></tr><tr><td rowspan=1 colspan=2>1.6%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>1410</td><td rowspan=1 colspan=2>12.9</td><td rowspan=1 colspan=1>15.7</td><td rowspan=2 colspan=1>1435</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>14.4</td></tr><tr><td rowspan=1 colspan=2>0.9%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.0%</td></tr></table>

Data at POL:

Precision - POL

# POL  Precision for ACE and ACE Alera Clinical Chemistry Systems

<table><tr><td rowspan=2 colspan=3>ALT</td><td rowspan=1 colspan=2>ACE Results</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>ACE Alera Results</td></tr><tr><td rowspan=1 colspan=2>U/L SD, %CV</td><td rowspan=1 colspan=2>Mean</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>U/L SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>33</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=2>32</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=2>32</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>26</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.7</td><td rowspan=2 colspan=2>28</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>8.4%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>27</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.8</td><td rowspan=2 colspan=2>26</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>8.2%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>30</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.7</td><td rowspan=2 colspan=2>29</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>8.4%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>191</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>4.8</td><td rowspan=2 colspan=2>190</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>189</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=2>193</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>192</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>5.9</td><td rowspan=2 colspan=2>194</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>188</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=2>195</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=2>195</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>309</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>3.7</td><td rowspan=2 colspan=2>307</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>304</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>4.4</td><td rowspan=2 colspan=2>309</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>311</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>10.2</td><td rowspan=2 colspan=2>314</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>303</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>5.0</td><td rowspan=2 colspan=2>310</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>9.1</td></tr><tr><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>

<table><tr><td>Data at POL:</td></tr><tr><td>Precision - POL</td></tr></table>

<table><tr><td rowspan=2 colspan=3>AST</td><td rowspan=1 colspan=2>ACE Results</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>ACE Alera Results</td></tr><tr><td rowspan=1 colspan=2>U/L SD, %CV</td><td rowspan=1 colspan=2>U/L SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>28</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.1</td><td rowspan=2 colspan=1>28</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>6.0%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>23</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.4</td><td rowspan=2 colspan=1>26</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>5.1%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>28</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.7</td><td rowspan=2 colspan=1>27</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>8.9%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>26</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.0</td><td rowspan=2 colspan=1>29</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>7.7%</td><td rowspan=1 colspan=1>9.9%</td><td rowspan=1 colspan=1>9.9%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>223</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>6.6</td><td rowspan=2 colspan=1>222</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>7.1</td></tr><tr><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>220</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>4.0</td><td rowspan=2 colspan=1>220</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>227</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>4.8</td><td rowspan=2 colspan=1>233</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>223</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>4.7</td><td rowspan=2 colspan=1>229</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>7.2</td></tr><tr><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>410</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>6.8</td><td rowspan=2 colspan=1>406</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>6.8</td></tr><tr><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>416</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>5.5</td><td rowspan=2 colspan=1>416</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>9.2</td></tr><tr><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>420</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>10.2</td><td rowspan=2 colspan=1>428</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>407</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>7.3</td><td rowspan=2 colspan=1>417</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>12.1</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>2.9%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Statistic</td><td rowspan=1 colspan=1>In-House ACE (x)vs.POL 1 ACE (y)</td><td rowspan=1 colspan=1>In-House ACE (x)vs.POL 2 ACE (y)</td><td rowspan=1 colspan=1>In-House ACE(x)vS.POL 3 ACE (y)</td></tr><tr><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>4958 to 1199y = 0.989x - 9.50.998712.40.975 to 1.004-13.8 to -5.1</td><td rowspan=1 colspan=1>5058 to 1199y = 0.977x - 7.90.99975.90.970 to 0.984-9.9 to -5.8</td><td rowspan=1 colspan=1>5058 to 1199y = 0.982x - 2.80.99957.40.973 to 0.990-5.4 to -0.2</td></tr><tr><td rowspan=1 colspan=1>AMY</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.Cl SlopeCI Intercept</td><td rowspan=1 colspan=1>5128 to 1732y = 0.970x + 1.50.999511.10.962 to 0.979-2.1 to 5.2</td><td rowspan=1 colspan=1>5128 to 1732y = 0.973x + 3.60.99987.50.967 to 0.9781.1 to 6.0</td><td rowspan=1 colspan=1>5128 to 1732y = 0.974x + 3.90.99987.40.968 to 0.9801.5 to 6.3</td></tr><tr><td rowspan=1 colspan=1>ALT</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.Cl SlopeCI Intercept</td><td rowspan=1 colspan=1>446 to 442y = 1.006x - 4.70.99786.50.985 to 1.026-6.9 to -2.4</td><td rowspan=1 colspan=1>476 to 442y = 1.021x - 4.00.99933.71.010 to 1.033-5.2 to -2.8</td><td rowspan=1 colspan=1>496 to 442y = 0.982x - 2.30.99815.70.964 to 0.999-4.1 to -0.4</td></tr><tr><td rowspan=1 colspan=1>AST</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>506 to 413y = 0.999x - 0.60.99933.90.988 to 1.010-1.9 to 0.6</td><td rowspan=1 colspan=1>506 to 413y = 1.019x + 2.40.99894.91.005 to 1.0330.9 to 4.0</td><td rowspan=1 colspan=1>506 to 413y = 0.992x + 0.60.99943.6 0.982 to 1.003-0.6 to 1.7</td></tr></table>

<table><tr><td>Performance Data: Method Comparison - POL on ACE</td></tr></table>

Performance Data at POL:

Method ComparisonPOL on ACE Alera

# POL  Method Comparison for ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Statistic</td><td rowspan=1 colspan=1>In-House ACE (x)vS.POL 1 Alera (y)</td><td rowspan=1 colspan=1>In-House ACE (x)vS.POL 2 Alera (y)</td><td rowspan=1 colspan=1>In-House ACE (x)vs.POL 3 Alera (y)</td></tr><tr><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>5058 to 1199y = 0.997x - 4.60.999210.10.985 to 1.008-8.1 to -1.1</td><td rowspan=1 colspan=1>5058 to 1199y= 1.029x - 4.10.999110.81.016 to 1.041-7.9 to -0.4</td><td rowspan=1 colspan=1>5058 to 1199y = 1.010x - 6.60.998613.00.995 to 1.025-1 1.2 to -2.1</td></tr><tr><td rowspan=1 colspan=1>AMY</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>5128 to 1732y = 0.960x + 3.00.999115.10.948 to 0.971-1.9 to 7.9</td><td rowspan=1 colspan=1>5128 to 1732y = 1.010x + 5.80.999511.71.001 to 1.0182.0 to 9.6</td><td rowspan=1 colspan=1>5128 to 1732y = 0.990x + 3.70.999511.30.981 to 0.9990.0 to 7.4</td></tr><tr><td rowspan=1 colspan=1>ALT</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCl Intercept</td><td rowspan=1 colspan=1>506 to 442y= 1.019x - 0.50.99865.11.003 to 1.035-2.1 to 1.1</td><td rowspan=1 colspan=1>486 to 442y = 1.012x - 3.50.99855.30.995 to 1.028-5.3 to -1.8</td><td rowspan=1 colspan=1>506 to 442y = 0.970x + 2.40.99776.10.951 to 0.9900.5 to 4.4</td></tr><tr><td rowspan=1 colspan=1>AST</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>506 to 413y = 1.028x + 1.40.99953.51.018 to 1.0370.3 to 2.5</td><td rowspan=1 colspan=1>506 to 413y = 1.040x + 0.50.99924.31.027 to 1.052-0.8 to 1.9</td><td rowspan=1 colspan=1>506 to 413y = 1.004x + 1.80.99953.30.994 to 1.0130.8 to 2.9</td></tr></table>

# Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE Alera Clinical Chemistry Systems

Detection Limits - ACE Alera Clinical Chemistry System

Linearity - ACE Alera Clinical Chemistry System   

<table><tr><td rowspan=1 colspan=1>ACE Alera</td><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>Amylase</td><td rowspan=1 colspan=1>ALT</td><td rowspan=1 colspan=1>AST</td></tr><tr><td rowspan=1 colspan=1>LoB (U/L)</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>LoD (U/L)</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>LoQ (U/L)</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>3.3</td></tr></table>

<table><tr><td rowspan=1 colspan=1>ACEReagents</td><td rowspan=1 colspan=1>Lowleveltested</td><td rowspan=1 colspan=1>Upperleveltested</td><td rowspan=1 colspan=1>Linear to:</td><td rowspan=1 colspan=1>LinearRegressionEquation</td><td rowspan=1 colspan=1>R^2</td></tr><tr><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>4.0U/L</td><td rowspan=1 colspan=1>1401 U/L</td><td rowspan=1 colspan=1>1400 U/L</td><td rowspan=1 colspan=1>y = 0.998x - 0.5</td><td rowspan=1 colspan=1>0.9993</td></tr><tr><td rowspan=1 colspan=1>Amylase</td><td rowspan=1 colspan=1>4.0U/L</td><td rowspan=1 colspan=1>2012 U/L</td><td rowspan=1 colspan=1>1900 U/L</td><td rowspan=1 colspan=1>y = 1.013x + 0.2</td><td rowspan=1 colspan=1>0.9974</td></tr><tr><td rowspan=1 colspan=1>ALT</td><td rowspan=1 colspan=1>3.1U/L</td><td rowspan=1 colspan=1>504 U/L</td><td rowspan=1 colspan=1>480 U/L</td><td rowspan=1 colspan=1>y = 1.007x - 0.17</td><td rowspan=1 colspan=1>0.9992</td></tr><tr><td rowspan=1 colspan=1>AST</td><td rowspan=1 colspan=1>3.0U/L</td><td rowspan=1 colspan=1>491 U/L</td><td rowspan=1 colspan=1>450 U/L</td><td rowspan=1 colspan=1>y = 1.013x + 0.24</td><td rowspan=1 colspan=1>0.9992</td></tr></table>

Performance Data:

ACE Alera

# Interferences - ACE Alera Clinical Chemistry System

Precision - ACE Alera Clinical Chemistry System   

<table><tr><td rowspan=2 colspan=1>Interferents onACE Alera</td><td rowspan=1 colspan=4>No Significant Interference at or below:</td></tr><tr><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>Amylase</td><td rowspan=1 colspan=1>ALT</td><td rowspan=1 colspan=1>AST</td></tr><tr><td rowspan=1 colspan=1>Icterus</td><td rowspan=1 colspan=1>70.6 mg/dL</td><td rowspan=1 colspan=1>30.0 mg/dL</td><td rowspan=1 colspan=1>50 mg/dL</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>62.5 mg/dL</td><td rowspan=1 colspan=1>62.5 mg/dL</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>62.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lipemia</td><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>419 mg/dL</td><td rowspan=1 colspan=1>439 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6 mg/dL</td><td rowspan=1 colspan=1>6 mg/dL</td><td rowspan=1 colspan=1>6 mg/dL</td><td rowspan=1 colspan=1>6 mg/dL</td></tr></table>

<table><tr><td rowspan=2 colspan=2>on ACE Alera</td><td rowspan=1 colspan=3>Precision (SD, %CV)</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ALPU/L</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0.9 , 2.2%</td><td rowspan=1 colspan=1>1.9 , 4.5%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>2.8 , 1.7%</td><td rowspan=1 colspan=1>5.5 , 3.4%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>339</td><td rowspan=1 colspan=1>5.3 , 1.6%</td><td rowspan=1 colspan=1>8.9 , 2.6%</td></tr><tr><td rowspan=3 colspan=1>AMYLASEU/L</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0.9 , 2.1%</td><td rowspan=1 colspan=1>1.5 , 3.3%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>1.7 , 1.2%</td><td rowspan=1 colspan=1>3.9 , 2.8%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>311</td><td rowspan=1 colspan=1>5.0 , 1.6%</td><td rowspan=1 colspan=1>7.7 , 2.5%</td></tr><tr><td rowspan=3 colspan=1>ALTU/L</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>1.2 , 3.3%</td><td rowspan=1 colspan=1>1.8 , 4.9%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>181</td><td rowspan=1 colspan=1>2.2 , 1.2%</td><td rowspan=1 colspan=1>3.2 , 1.8%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>5.2 , 1.6%</td><td rowspan=1 colspan=1>5.2 , 1.6%</td></tr><tr><td rowspan=3 colspan=1>ASTU/L</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>1.1 , 3.3%</td><td rowspan=1 colspan=1>1.5 , 4.4%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>175</td><td rowspan=1 colspan=1>3.5 , 2.0%</td><td rowspan=1 colspan=1>3.6 , 2.1%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>4.8 , 1.5%</td><td rowspan=1 colspan=1>4.9 , 1.6%</td></tr></table>

In-House ACE (x) vs. In-House ACE Alera (y)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>Amylase</td><td rowspan=1 colspan=1>ALT</td><td rowspan=1 colspan=1>AST</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Range (U/L)</td><td rowspan=1 colspan=1>9 to 1199</td><td rowspan=1 colspan=1>10 to 1732</td><td rowspan=1 colspan=1>6 to 442</td><td rowspan=1 colspan=1>6 to 413</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.991</td><td rowspan=1 colspan=1>0.995</td><td rowspan=1 colspan=1>0.988</td><td rowspan=1 colspan=1>1.006</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>0.9999</td><td rowspan=1 colspan=1>0.9998</td><td rowspan=1 colspan=1>0.9999</td><td rowspan=1 colspan=1>0.9998</td></tr><tr><td rowspan=1 colspan=1>Std. Error</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>CI Slope</td><td rowspan=1 colspan=1>0.987 to 0.9950.990 to 1.000</td><td rowspan=1 colspan=1>0.987 to 0.9950.990 to 1.000</td><td rowspan=1 colspan=1>0.983 to 0.992</td><td rowspan=1 colspan=1>21.001 to 1.012</td></tr><tr><td rowspan=1 colspan=1>CI Intercept</td><td rowspan=1 colspan=1>-0.5 to 1.6</td><td rowspan=1 colspan=1>0.9 to 4.9</td><td rowspan=1 colspan=1>0.8 to 1.8</td><td rowspan=1 colspan=1>0.9 to 2.2</td></tr></table>

<table><tr><td>Performance Data: ACE Alera</td></tr><tr><td>Conclusions:</td></tr></table>

<table><tr><td>Conclusions:</td><td>Based on the foregoing data, the device is safe and effective for use in clinical laboratories and physician office laboratories. These data indicate substantial equivalence for lithium heparin plasma sample collection tubes to the predicate device&#x27;s use of serum sample collection tubes.</td></tr></table>

# August 15, 2013

Alfa Wassermann Diagnostic Technologies, LLC C/O Hyman Katz, Ph.D.   
4 Henderson Drive   
WEST CALDWELL NJ 07006

Re: K131351 Trade/Device Name: ACE Alkaline Phosphatase Reagent ACE Amylase Reagent ACE ALT Reagent ACE AST Reagent Regulation Number: 21 CFR 862. 1050 Regulation Name: Alkaline phosphatase or isoenzymes test system Regulatory Class: II Product Code: CJE, CIJ, CKA, CIT Dated: July 8, 2013 Received: July 9, 2013

Dear Dr. Katz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please ncte: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements conceming your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2-Dr. Katz

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersQfficcs/CDRH/CDRHOffices/ucm!15809.htm for the Center Sor Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go t0   
http:/www.fda.gov/MedicalDevices/Safcty/RcportaProblem/default.hum for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilitics under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address hup://www.Ida.gov/MedicalDevices/ResourcesforYou/Industry/dcfault.htm.

Sincerely yours, Carol C. Benson -S for

Courtney H. Lias. Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Deviccs and Radiological Health

# Indications for Use

Device Name:

ACE Alkaline Phosphatase Reagent

Indications for Use: The ACE Alkaline Phosphatase Reagent is intended for the quantitative determination of alkaline phosphatase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Measurements of alkaline phosphatase are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.

# Device Name:

ACE Amylase Reagent

Indications for Use: The ACE Amylase Reagent is intended for the quantitative determination of α-amylase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Amylase measurements are used primarily for the diagnosis and treatment of pancreatitis (inflammation of the pasTh   u  cl physician office laboratories. For in vitro diagnostic use only.

# Concurrence of CDRH, Office of In Vitro Devices or Radiological Health (OIR)

Ruth A. Chesler -S

# Indications for Use

Device Name: ACE ALT Reagent

Indications for Use: The ACE ALT Reagent is intended for the quantitative determination of alanine aminotransferase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Alanine aminotransferase measurements are used in the diagnosis and treatment of certain liver diseases (e.g., viral hepatitis and cirrhosis) and heart diseases. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.

# Device Name: ACE AST Reagent

# Indications for Use:

The ACE AST Reagent is intended for the quantitative determination of aspartate aminotransferase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Measurements of aspartate aminotransferase are used in the diagnosis and treatment of certain types of liver and heart disease. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.

# Concurrence of CDRH, Office of In Vitro Devices or Radiological Health (OIR)

Ruth A. Chesler -S